The manufacturing process for cultured meat has historically been difficult and expensive. We are thrilled to partner with the Prolific Machines team as they pioneer a unique manufacturing approach for cultured meat cells and beyond that will transform industries by creating an assembly line for biology. Arvind shares five insights from investing in Prolific below.
Mammoth Biosciences CEO & Co-founder Trevor Martin joined Mayfield’s Ursheet at TechCrunch Live for a candid conversation on Mammoth’s inception to iconic journey. Watch the recording to learn how to create built to last relationships with co-founders and investors, align around the vision and mission, recruit a world-class team, turn an audacious goal into tangible progress, and more.
Arvind sat down with Megan Hernbroth at Axios to share insights into his investment strategies and the future of climate technology. He was also featured in a Q&A by BIOS where he shared advice for founders preparing to fundraise, what he looks for in founders and inception-stage companies, finding product-market-fit in capex heavy companies, and more.
UBCO, the global leader in electric utility vehicles, has partnered with cutting edge AI-powered battery platform Chemix to commercialize sustainable, ultra-safe, and high-energy cobalt-free (Co-free) Li-ion battery technology. Chemix is using AI to develop battery chemistries similar to how AI has been applied to speed up drug development, and this collaboration will help reduce battery dependence on rare earth minerals.
Endpoint Health has acquired Iconic Therapeutics as part of its newest precision immunology program, which aims to transform immune-mediated inflammatory disease treatment with novel precision medicine strategies. The team also welcomed Ransi Somaratne, M.D. as their first Chief Medical Officer to lead the company’s clinical strategy and drug development programs.
Mirvie, a pioneer in predicting unexpected pregnancy complications, has welcomed Alison Cowan as Head of Medical Affairs. Dr. Cowan will guide Mirvie’s continued clinical and commercial development of the proprietary Mirvie RNA platform, which is first to predict preeclampsia and preterm birth months before they happen by revealing the underlying biology of each pregnancy.
